Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Sep;17(3):138-47.
doi: 10.3132/pcrj.2008.00004.

Factors accounting for asthma variability: achieving optimal symptom control for individual patients

Affiliations
Review

Factors accounting for asthma variability: achieving optimal symptom control for individual patients

Barbara P Yawn. Prim Care Respir J. 2008 Sep.

Abstract

Asthma is a variable disease, and various factors can lead to an increase (or decrease) in asthma symptoms and the level of asthma control. Pub Med was searched for recent articles dealing with asthma variability, environmental factors and co-morbid conditions that affect asthma control, and for publications which identified tools to facilitate patients' response to asthma variability. Variability in asthma symptoms may be a response to the individual's environment (e.g. seasonal variation, cigarette smoke, and air pollutants) or personal factors (e.g. inhaler technique, pregnancy, exercise). Co-morbid diseases such as allergic rhinitis may also impact significantly on asthma variability and control. Documenting asthma variability and assessing both adherence and possible triggers over time may allow patients and physicians to develop treatment programmes that anticipate, rather than follow, changes in the level of asthma symptoms. Personalised asthma control plans which take into account factors affecting symptom variability may enable patients to modify medication and their environment prophylactically in anticipation of a known trigger or at the first sign of an asthma exacerbation.

PubMed Disclaimer

Conflict of interest statement

The author is a member of the National Institutes of Health's National Asthma Education and Prevention Program and the National Heart, Lung, and Blood Institute's Expert Review Panel 3 for updating asthma guidelines. She serves on the National Patient and Professional Asthma Advisory Committee for AstraZeneca and the Schering-Plough National Respiratory Disease Leadership Council, and has served as a consultant to Altana Pharma for asthma-related topics. She also has research grants in asthma-related topics from the National Heart, Lung, and Blood Institute, and the Agency for HealthCare Research and Quality and Schering-Plough Integrated Therapeutics.

Publication types